EXCHANGE AGREEMENT
Exhibit 10.4
THIS EXCHANGE AGREEMENT (this “Agreement”) is made effective as of this 11th day of June, 2010, by and between Socius XX XX, Ltd., a Bermuda exempted company (“Socius”), and International Stem Cell Corporation, a Delaware corporation (the “Company”).
WHEREAS, on May 4, 2010 the parties entered into a Preferred Stock Purchase Agreement (the “Purchase Agreement”) pursuant to which Socius agreed to purchase One Thousand (1,000) shares of the Company’s Series F Preferred Stock (the “Preferred Stock”) and received a warrant to purchase up to 7,000,000 shares of the Company’s common stock (the “Warrant”);
WHEREAS, the Preferred Stock accrues a dividend in shares of Series F Preferred Stock on a daily basis at a rate equal to 10% per annum from the date of issuance with the dividend being payable on the date the Preferred Stock is redeemed (the “Dividend”);
WHEREAS, the Preferred Stock is redeemable commencing one year after its issuance, subject to payment of redemption premiums that start at 26% and decline to 0% after the Preferred Stock has been outstanding for four years (the “Redemption Premiums”);
WHEREAS, on May 5, 2010, Socius exercised the Warrant for 7,000,000 shares of Company common stock at an exercise price of $1.92857150 per share and a total purchase price of $13,500,000, all of which was paid by delivery to the Company of a secured note accruing interest at 2% per annum (the “Warrant Note”);
WHEREAS, on June 4, 2010, the Company issued Socius 1,000 shares of the Preferred Stock for a total purchase price of $10,000,000, $7,500,000 of which was paid in cash and $2,500,000 of which was paid in a secured note accruing interest at 2% per annum (the “Preferred Note”);
WHEREAS, Socius has offered to exchange the Preferred Stock and to waive all Dividends (collectively, the “Preferred Stock Exchange”) in return for the cancellation of the Warrant Note and the Preferred Note and the waiver of all interest on the Warrant Note and the Preferred Note (collectively, the “Debt Exchange”), and the other terms set forth in this Agreement, and the Company desires to accept such offer; and
WHEREAS, Socius and the Company, each being a willing party to this transaction and neither being under any compulsion to exchange the instruments, rights and benefits being exchanged pursuant to this Agreement, acknowledge that they are each aware of the relevant facts relating to the exchange (including, without limitation, (i) the differences between the interest rates on the Warrant Note and the Preferred Note and the dividend rates on the Preferred Stock, (ii) the Redemption Premiums payable once the Preferred Stock is redeemable, (iii) the fact that the Preferred Stock is not yet redeemable, and (iv) the various benefits to each party under the contemplated exchange, which the parties have agreed offset the difference between the principal amount of the Warrant Note and the Preferred Note and the liquidation preference of the Preferred Stock), and further acknowledge and agree that, in total, the instruments, rights and benefits being exchanged by each side are of equivalent value.
1
NOW, THEREFORE, in consideration of the mutual covenants and agreements hereinafter set forth, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:
ARTICLE I
TRANSACTIONS
Section 1.1 Sale. The Company and the Socius hereby agree to consummate the Preferred Stock Exchange and the Debt Exchange. In furtherance of the foregoing, effective as of the Closing:
(a) Socius hereby waives the requirement that the Preferred Stock be held by Socius for one year prior to redemption by the Company;
(b) Socius hereby waives the Redemption Premiums owing to it pursuant to the Preferred Stock Agreement and/or the Certificate of Designation of Preferences, Rights and Limitations of Series F Preferred Stock (the “Certificate of Designation”);
(c) Socius hereby waives the Dividend owed to it through the Closing pursuant to the Preferred Stock Agreement and/or the Certificate of Designation;
(d) The Company hereby waives any interest owed to it through the Closing under both the Warrant Note and the Preferred Note;
(e) The Company hereby cancels the Warrant Note and the Preferred Note;
(f) Socius hereby agrees to return all of the shares of Preferred Stock to the Company for cancellation; and
(g) The Company and Socius acknowledge that the Preferred Stock Exchange and Debt Exchange shall affect a release by the Company and Socius of all continuing rights each party holds, and all obligations owed to the other, under the Purchase Agreement; provided, however, that such release shall not apply to any rights or obligations arising from or related to any securities of the Company that Socius continues to own as of and/or after the date hereof.
Section 1.2 Closing. The closing of the transactions contemplated by this Agreement (the “Closing”) shall be held at the offices of DLA Piper LLP (US), counsel to the Company, at 0000 Xxxxxxxxx Xxxxx, Xxxxx 0000, Xxx Xxxxx, Xxxxxxxxxx 00000 on the date hereof (the “Closing Date”), or at such other time and place as the Company and Socius may agree either in writing or orally. At the Closing:
(a) Socius will deliver the Certificate representing the shares of Preferred Stock to the Company evidencing the Preferred Stock Exchange.
(b) The Company will cancel the Preferred Stock, will cancel the Warrant Note and the Preferred Note evidencing the Debt Exchange, and will deliver the cancelled Warrant Note and Preferred Note to Socius; and
2
(c) The other waivers, cancellations and releases set forth in Section 1.1 shall be effective.
ARTICLE II
REPRESENTATIONS AND WARRANTIES
Section 2.1 Representations and Warranties of the Company. The Company hereby represents and warrants to Socius as of the date hereof as follows:
(a) The Company has the requisite corporate power and authority to enter into this Agreement and to consummate the transactions contemplated by the Agreement and otherwise to carry out its obligations hereunder. The execution and delivery of the Agreement by the Company and the consummation by it of the transactions contemplated hereby have been duly authorized by all necessary action on the part of the Company and no further consent or action is required by the Company. The Agreement has been (or upon delivery will be) duly executed by the Company and, when delivered in accordance with the terms hereof, will constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, subject to applicable bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and similar laws affecting creditors’ rights and remedies generally and general principles of equity.
(b) The execution, delivery and performance of the Agreement by the Company and the consummation by the Company of the transactions contemplated hereby do not and will not (i) conflict with or violate any provision of the Company’s certificate of incorporation, as amended, or bylaws, or (ii) conflict with or violate the terms of any material agreement by which the Company is bound or to which any property or asset of the Company is bound or affected.
(c) The Company has full title to and ownership of the Warrant Note, the Preferred Note and all rights being waived, cancelled or released hereunder.
Section 2.2 Representations, Warranties and Covenants of Socius. Socius hereby represents and warrants to the Company as of the date hereof as follows:
(a) Socius has the requisite power and authority to enter into this Agreement, to consummate the transactions contemplated by this Agreement and otherwise to carry out its obligations hereunder. The execution and delivery of the Agreement by Socius and the consummation by it of the transactions contemplated hereby have been duly authorized by all necessary action on the part of Socius and no further consent or action is required by Socius. The Agreement has been (or upon delivery will be) duly executed by Socius and, when delivered in accordance with the terms hereof, will constitute the valid and binding obligation of Socius enforceable against Socius in accordance with its terms, subject to applicable bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and similar laws affecting creditors’ rights and remedies generally and general principles of equity.
(b) The execution, delivery and performance of the Agreement by Socius and the consummation by Socius of the transactions contemplated hereby do not and will not (i) conflict with or violate any provision of Socius’s organizational documents, or (ii) conflict with or violate the terms of any material agreement by which Socius is bound or to which any property or asset of Socius is bound or affected.
3
(c) Socius has full title to and ownership of the Preferred Stock and all rights being waived, cancelled or released hereunder.
ARTICLE III
MISCELLANEOUS
Section 3.1 Entire Agreement. This Agreement constitutes the entire agreement of the parties hereto with respect to the subject matter hereof and thereof and supersedes all prior agreements and undertakings, both written and oral, between or among the parties hereto with respect to the subject matter hereof and thereof.
Section 3.2 Amendment. This Agreement may not be amended or modified except by an instrument in writing signed by, or on behalf of, each party hereto.
Section 3.3 No Third Party Beneficiaries. This Agreement shall be binding upon and inure solely to the benefit of the parties hereto and their respective successors and permitted assigns and nothing herein, express or implied, is intended to or shall confer upon any other person any legal or equitable right, benefit or remedy of any nature whatsoever under or by reason of this Agreement.
Section 3.4 Governing Law. This Agreement shall be governed by, and construed in accordance with, the laws of the State of New York.
Section 3.5 Counterparts. This Agreement may be executed and delivered (including by facsimile or other electronic transmission) in one or more counterparts, and by the parties hereto in separate counterparts, each of which when executed shall be deemed to be an original, but all of which taken together shall constitute one and the same agreement. This Agreement may be executed by facsimile or other electronic transmission.
[Signatures on following page]
4
IN WITNESS WHEREOF, the parties hereto have executed this Exchange Agreement as of the date first written above.
| COMPANY: | ||
| INTERNATIONAL STEM CELL CORPORATION | ||
| By: | /s/ Xxx Xxxx | |
| Name: | Xxx Xxxx | |
| Title: | Chief Financial Officer | |
| SOCIUS XX XX, LTD.: | ||
| By: | /s/ Xxxxxx Xxxxxx | |
| Name: | Xxxxxx Xxxxxx | |
| Title: | Managing Director | |
5
